Vivek Subbiah: A clinical trial is not a last resort but can be a first option for people facing cancer.
Vivek Subbiah, Chief, Early-Phase Drug Development at , shared a post by Sarah Cannon Research Institute on LinkedIn, adding:
“Throughout my career, I have had a front-row seat to the impact cancer research makes for patients in clinical trials and beyond.
A clinical trial is not a last resort but can be a first option for people facing cancer.
This World Cancer Research Day, here are 3 key insights for patients considering clinical trials.”
Quoting Sarah Cannon Research Institute’s post:
“On this World Cancer Research Day, SCRI’s Chief of Early-Phase Drug Development, Vivek Subbiah, MD, shares, “In this era of personalized medicine, clinical trials hold great promise for patients with cancer by providing tailored treatments that are more effective, reducing side effects, contributing to medical research, and offering hope for those facing challenging cancer diagnoses.” Learn about more key insights for patients considering a clinical trial: here.”
Sources: Vivek Subbiah/LinkedIn and Sarah Cannon Research Institute/LinkedIn